Natco Pharma Limited — Board Meeting, 28-05-2025: Outcome of Board Meeting

NATCO Pharma has announced a board meeting on the approval of its consolidated financial results for FY25. The company posted record consolidated revenue of ₹4,784 Cr, up 16% YoY, with net profit jumping 36% to ₹1,883 Cr. Q4 revenue reached ₹1,287 Cr, with profit at ₹406 Cr, slightly above last year. Crop Health Sciences took a ₹50 Cr impairment, and the US business faced a ₹25 Cr chargeback. NATCO closed FY25 with over ₹3,000 Cr in cash but warns of a potential 20% revenue and 30% profit decline in FY26 due to US market challenges and increased R&D spend.